| Literature DB >> 29126396 |
Marion Kiechle1, Ricarda Dukatz2, Maryam Yahiaoui-Doktor3, Anika Berling4, Maryam Basrai5, Vera Staiger5, Uwe Niederberger6, Nicole Marter6, Jacqueline Lammert2, Sabine Grill2, Katharina Pfeifer2, Kerstin Rhiem7, Rita K Schmutzler7, Matthias Laudes8, Michael Siniatchkin6, Martin Halle4,9, Stephan C Bischoff6, Christoph Engel3.
Abstract
BACKGROUND: Women with pathogenic BRCA germline mutations have an increased risk for breast and ovarian cancer that seems to be modified by life-style factors. Though, randomized trials investigating the impact of lifestyle interventions on cancer prevention and prognosis in BRCA carriers are still missing.Entities:
Keywords: BRCA1; BRCA2; Exercise; Hereditary breast cancer; Hereditary ovarian cancer; Mediterranean diet; Psychological support
Mesh:
Substances:
Year: 2017 PMID: 29126396 PMCID: PMC5681801 DOI: 10.1186/s12885-017-3732-4
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Baseline characteristics of study participants
| Intervention group | Control group | Total |
| |
|---|---|---|---|---|
| Cancer, n | 23 | 23 | 46 | 0.728 |
|
| 24 / 9 | 18 / 17 | 42 / 26 | 0.073 |
| Agea, yrs | 41 (27–72) | 41 (24–68) | 41 (24–72) | 0.839 |
| BMIa, kg/m2 | 22.2 (18.0–45.4) | 23.6 (18.3–42.2) | 23.2 (18.0–45.4) | 0.482 |
| VO2peaka, ml/kg/min | 24 (12–42) | 28 (15–38) | 26 (12–42) | 0.597 |
| Drop-out, n | 7 | 6 | 13 | 0.672 |
aMedian (Range)
Fig. 1CONSORT flow diagram for LIBRE-1 pilot study [45]
Baseline characteristic of drop-outs
| Drop-outs | Intervention group | Control group | Total |
|
|---|---|---|---|---|
| Drop-out period, n | 0.945 | |||
| - Months 1–3 | 5 | 4 | 9 | |
| Reason, n | 0.445 | |||
| - Motivation-related | 4 | 5 | 9 | |
| Cancer, n | 5 | 4 | 9 | 0.945 |
| Agea, years | 45 (30–51) | 34 (26–46) | 39 (26–51) | 0.138 |
| BMIa, kg/m2 | 20.9 (19.8–26.9) | 23.7 (20.7–38.6) | 23.1 (19.8–38.6) | 0.138 |
| VO2peaka, ml/kg/min | 30 (20–32) | 24.5 (16–34) | 26 (16–34) | 0.543 |
| O2 at VT1a, ml/kg/min | 14 (9–19) | 13.5 (10–25) | 14 (9–25) | 0.731 |
| IPAQ, METamin/wk | 3366 (1552–12,561) | 9750 (4278–14,085) | 3990 (1552–14,085) | 0.042 |
aMedian (Range)
Adherence to the lifestyle intervention program within the first 3 months and baseline characteristics (n = 26)
| Adherence positive | Adherence negative |
| |
|---|---|---|---|
| Nutrition courses | 21/26 (81%) | 5/26 (19%) | |
| Cancer, n | 16 | 2 | 0.610 |
| Age*, years | 43 (29–72) | 41 (28–49) | 0.686 |
| BMI*, kg/m2 | 23 (18–45) | 24 (20–37) | 0.610 |
| VO2peak*, ml/kg/min | 24 (12–42) | 23 (16–41) | 0.952 |
| O2 at VT1*, ml/kg/min | 14 (8–28) | 14 (10–21) | 0.343 |
| IPAQ, MET*min/wk | 5130 (347–14,166) | 6167 (4583–7812) | 0.629 |
| Training courses | 21/26 (81%) | 5/26 (19%) | |
| Cancer, n | 14 | 4 | 0.114 |
| Age*, years | 42 (28–72) | 41 (36–51) | 0.286 |
| BMI*, kg/m2 | 23 (18–45) | 24 (20–37) | 0.857 |
| VO2peak*, ml/kg/min | 24 (12–42) | 22 (16–37) | 0.467 |
| O2 at VT1*, ml/kg/min | 14 (8–28) | 15 (10–21) | 1.000 |
| IPAQ, MET*min/wk | 5376 (347–14,166) | 5375 (2826–7812) | 0.970 |
| Nutrition and training | 19/26 (73%) | 7/26 (27%) | |
| Cancer, n | 14 | 4 | 0.534 |
| Age*, years | 43 (29–27) | 41 (28–51) | 0.821 |
| BMI*, kg/m2 | 23 (18–45) | 24 (20–37) | 0.778 |
| VO2peak*, ml/kg/min | 24 (12–42) | 23 (16–41) | 0.955 |
| O2 at VT1*, ml/kg/min | 14 (8–28) | 15 (10–21) | 0.642 |
| IPAQ, MET*min/wk | 5376 (347–14,166) | 5576 (2826–7812) | 0.974 |
*Median (Range)
Participants satisfaction with the study
| Rate of return | Intervention group | Control group |
| ||||
|---|---|---|---|---|---|---|---|
| Items | “Good” | “Inter-mediate” | “Bad” | “Good” | “Inter-mediate” | “Bad” | |
| Overall satisfaction with the study and care | 15 (83%) | 3 (17%) | 0 (0%) | 14 (64%) | 7 (32%) | 1 (4.5%) | 0.096 |
| Extent and feasibility of physical intervention (IG) | 10 (56%) | 5 (28%) | 3 (17%) | not asked | |||
| Extent and feasibility of nutritional intervention (IG) | 14 (78%) | 4 (22%) | 0 (0%) | not asked | |||
| Extent and feasibility of general information on training and healthy eating (CG) | not asked | 9 (41%) | 10 (45%) | 2 (9%) | |||
| yes | No | yes | no |
| |||
| Willingness to partake in such studies again | 15 (83%) | 3 (17%) | 17 (77%) | 5 (23%) | 0.683 | ||
Secondary endpoints
| Intervention group | Control group |
| |
|---|---|---|---|
| Body Mass Index, kg/m2 | |||
| Baseline (V0) | 22 .2 (18.0–45.2) ( | 23.6 (18.3–42.7) ( | 0.482 |
| 3 Months (V1) | 23.4 (17.3–44.8) ( | 24.4 (18.3–44.8) ( | 0.804 |
| 12 Months (V2) | 24.1 (18.6–46.3) | 23.3 (18.6–46.3) ( | 0.833 |
| Δ V1-V0 | −0.19 (−4.7–0.8) ( | 0.32 (−1.1–2.2) ( | 0.002 |
| Δ V2-V0 | −0.16 (−7.6–2.8) ( | 0.034 (−1.9–3.6) ( | 0.115 |
| EPIQ-FFQ: energy intake, kcal/day | |||
| Baseline (V0) | 1955.2 (863.8–3530.5) ( | 2245.4 (1060.4–3088.3) ( |
|
| 3 Months (V1) | 2240.2 (800.7–3673.0) ( | 2085.8 (780.7–2965.8) ( | 0.761 |
| 12 Months (V2) | 2024.6 (989.0–3516.9) ( | 1936.0 (308.1–3609.9) ( | 0.405 |
| Δ V1-V0 | 78.8 (−1048.1–834.1) ( | −149.4 (−741.4–653.7) ( | 0.119 |
| Δ V2-V0 | 133.3 (−962.3–634.0) ( | −112.6 (−1383.2–547.8) ( |
|
| EPIQ-FFQ: Fat calorie intake [%energy intake] | |||
| Baseline (V0) | 40.1 (28.7–67.9) ( | 40.4 (31.4–50.0) ( | 0.968 |
| 3 Months (V1) | 39.4 (31.3–63.1) ( | 40.3 (30.9–60.0) ( | 0.910 |
| 12 Months (V2) | 40.2 (33.5–66.9) ( | 39.2 (27.1–50.6) ( | 0.504 |
| Δ V1 - V0 | 0.35 (−14.32–8.38) ( | 0.49 (−11.01–15.15) ( | 0.971 |
| Δ V2 - V0 | −1.30 (−6.69–26.61) ( | −2.22 (−13.16–14.25) ( | 0.367 |
| MEDAS: (0–14 score points) | |||
| Baseline (V0) | 7 (2–10) ( | 5 (3–11) ( | 0.020 |
| 3 Months (V1) | 9 (6–13) ( | 6 (3–12) ( | 0.001 |
| 12 Months (V2) | 8 (5–13) ( | 6 (2–13) ( | 0.001 |
| Δ V1-V0 | 2 (−1–8) ( | 1 (−3–4) ( | 0.110 |
| Δ V2-V0 | 2 (−2–6) ( | 0 (−3–6) ( | 0.044 |
| IPAQ, MET*min/wk | |||
| Baseline (V0) | 4583 (347–14,166) ( | 4215 (300–15,624) ( | 0.294 |
| 3 Months (V1) | 4447 (834–11,904) ( | 3230 (173–37,788) ( | 0.212 |
| 12 Months (V2) | 3754 (1012–11,706) ( | 4528 (189–56,943) ( | 0.463 |
| Δ V1-V0 | 252 (−7961–4878) ( | −125 (−14,085–22,164) [ | 0.654 |
| Δ V2-V0 | −1878 (−10,236–6084) ( | 961 (−4178–41,310) ( | 0.004 |
| VO2peak, ml/kg/min | |||
| Baseline (SE-V0) | 24 (12–42) ( | 28 (15–38) ( | 0.597 |
| 3 Months (V1) | 26 (15–42) ( | 27 (14–40) ( | 0.993 |
| 12 Months (V2) | 24 (10–35) ( | 26 (14–44) ( | 0.459 |
| Δ V1-V0 | 2 (−6–10) ( | 0 (−7–6) ( | 0.146 |
| Δ V2-V0 | −1 (−13–11) ( | −3 (−9–6) ( | 0.045 |
| O2 at VT1, ml/kg/min | |||
| Baseline (SE/V0) | 14 (8–28) ( | 16 (10–28) ( | 0.281 |
| 3 Months (V1) | 15 (9–28) ( | 15 (10–39) ( | 0.787 |
| 12 Months (V2) | 14 (6–26) ( | 16 (8–28) ( | 0.068 |
| Δ V1-V0 | 1 (−11–5) ( | −1.5 (−9–18) ( | 0.019 |
| Δ V2-V0 | 0 (−12–8) ( | 0 (−10–7) ( | 1.000 |
| QLQ-C30 scale 1 (0–100 scores) | |||
| Baseline (SE/V0) | 68.7 (17–100) ( | 69.1 (33–100) ( | 0.938 |
| 3 Months (V1) | 69.9 (0–100) ( | 73.3 (17–100) ( | 0.569 |
| 12 Months (V2) | 70.1 (25–100) ( | 63.1 (8–100) ( | 0.309 |
| Δ V1-V0 | 1.3 ( | 3.3 ( | 0.603 |
| Δ V2-V0 | 2.1 ( | −4.8 ( | 0.267 |
| SSCS (0–48 scores) | |||
| Baseline (SE/V0) | 15.3 (3–38) ( | 19.5 (0–38) ( | 0.062 |
| 3 Months (V1) | 16.0 (3–37) ( | 18.2 (0–39) ( | 0.339 |
| 12 Months (V2) | 14.6 (3–41) ( | 20.9 (1–39) ( | 0.022 |
| Δ V1-V0 | 0.4 ( | −0.9 ( | 0.388 |
| Δ V2-V0 | −0.6 ( | 1.44 ( | 0.218 |
*Median (Range)
Bold = significant P-values